If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
The Latest on: Precision cancer medicine
via Google News
The Latest on: Precision cancer medicine
- How precision medicine can help cancer patients on October 4, 2018 at 2:08 pm
A man receives a chemotherapy injection at the Harold Alfond Center for Cancer Care in Augusta, Maine. Photo: Michael G. Seamans/Portland Press Herald via Getty Images Last year, the FDA issued a land... […]
- Irving cancer-fighter raises $150 million to expand precision medicine research on October 1, 2018 at 10:22 am
An Irving life sciences firm has raised $150 million from one of the nation's largest investment houses to expand its cancer-fighting genetic sequencing research and development. TPG Sixth Street Part... […]
- Journey to precision cancer treatment takes off with new passports tool on October 1, 2018 at 9:49 am
Cancer research and the future of precision cancer treatment will be accelerated by a new tool developed by scientists at the Wellcome Sanger Institute. The novel tool, called Cell Model Passports, ac... […]
- Precision Therapeutics Harnesses Artificial Intelligence to Help Discover the Next Generation of Personalized Cancer Therapies on October 1, 2018 at 7:15 am
Through its acquisition of Helomics, Precision Therapeutics will ... the hope is to be use it to help guide treatment options for a wide range of cancer patients. Meanwhile, it's also in the ... […]
- Northshore University HealthSystem releases test to predict risk of prostate cancer on October 1, 2018 at 5:00 am
Evanston, Ill.-based Northshore University HealthSystem's center for personalized medicine rolled out a new test to assess patients' risk of developing prostate cancer. NorthShore developed the test, ... […]
- Making precision medicine a reality for children with cancer on September 27, 2018 at 3:02 am
Children are not little adults. From the time of birth, the few trillion cells making up a newborn baby, must rapidly proliferate, adapt and differentiate in a co-ordinated manner throughout childhood ... […]
- These Precision-Medicine Biotechs Show Promise In Lung Cancer on September 26, 2018 at 6:31 am
On the stock market today, Blueprint stock popped 3.7%, to close at 77.96. In two lung-cancer patients with specific genetic mutations, the regimen that included Blueprint's BLU-667 drug shrank tumors ... […]
- Is 'precision medicine' the answer to cancer? Not precisely on September 19, 2018 at 8:33 am
Facing incurable breast cancer at age 55, MaryAnne DiCanto put her faith in "precision medicine" in which doctors try to match patients with drugs that target the genetic mutations in their tumors. Sh... […]
- Analysis: Is ‘precision medicine’ the answer to cancer? Not precisely on September 17, 2018 at 2:24 pm
Facing incurable breast cancer at age 55, MaryAnne DiCanto put her faith in “precision medicine” — in which doctors try to match patients with drugs that target the genetic mutations in their tumors. ... […]
via Bing News